# Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

> **NCT01553123** · PHASE3 · WITHDRAWN · sponsor: **Watson Pharmaceuticals**

## Conditions studied

- Leiomyomas

## Interventions

- **DRUG:** Ulipristal Acetate
- **DRUG:** Iron

## Key facts

- **NCT ID:** NCT01553123
- **Lead sponsor:** Watson Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-04
- **Primary completion:** 2013-11
- **Final completion:** 2013-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01553123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01553123, "Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01553123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*